GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avid Bioservices Inc (NAS:CDMO) » Definitions » Beneish M-Score

CDMO (Avid Bioservices) Beneish M-Score : -4.69 (As of Dec. 14, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Avid Bioservices Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.69 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Avid Bioservices's Beneish M-Score or its related term are showing as below:

CDMO' s Beneish M-Score Range Over the Past 10 Years
Min: -6.48   Med: -2.25   Max: 17.81
Current: -4.69

During the past 13 years, the highest Beneish M-Score of Avid Bioservices was 17.81. The lowest was -6.48. And the median was -2.25.


Avid Bioservices Beneish M-Score Historical Data

The historical data trend for Avid Bioservices's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avid Bioservices Beneish M-Score Chart

Avid Bioservices Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.18 -2.44 17.81 -2.04 -3.44

Avid Bioservices Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.38 -1.63 -3.44 -4.00 -4.69

Competitive Comparison of Avid Bioservices's Beneish M-Score

For the Biotechnology subindustry, Avid Bioservices's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avid Bioservices's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avid Bioservices's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Avid Bioservices's Beneish M-Score falls into.



Avid Bioservices Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Avid Bioservices for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1684+0.528 * 1.6312+0.404 * 0.0511+0.892 * 1.0675+0.115 * 0.73
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0883+4.679 * -0.466409-0.327 * 1.4432
=-4.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Oct24) TTM:Last Year (Oct23) TTM:
Total Receivables was $30.2 Mil.
Revenue was 33.482 + 40.173 + 42.975 + 33.815 = $150.4 Mil.
Gross Profit was -2.045 + 5.713 + 5.5 + 2.383 = $11.6 Mil.
Total Current Assets was $96.5 Mil.
Total Assets was $323.5 Mil.
Property, Plant and Equipment(Net PPE) was $222.6 Mil.
Depreciation, Depletion and Amortization(DDA) was $12.5 Mil.
Selling, General, & Admin. Expense(SGA) was $31.9 Mil.
Total Current Liabilities was $74.2 Mil.
Long-Term Debt & Capital Lease Obligation was $204.1 Mil.
Net Income was -17.406 + -5.534 + -123.104 + -6.006 = $-152.1 Mil.
Non Operating Income was -1.499 + -0.624 + -2.126 + -2.184 = $-6.4 Mil.
Cash Flow from Operations was 3.994 + -3.68 + 1.257 + 3.687 = $5.3 Mil.
Total Receivables was $24.2 Mil.
Revenue was 25.395 + 37.726 + 39.799 + 38.018 = $140.9 Mil.
Gross Profit was -4.665 + 4.1 + 8.391 + 9.825 = $17.7 Mil.
Total Current Assets was $104.2 Mil.
Total Assets was $454.6 Mil.
Property, Plant and Equipment(Net PPE) was $229.1 Mil.
Depreciation, Depletion and Amortization(DDA) was $9.2 Mil.
Selling, General, & Admin. Expense(SGA) was $27.5 Mil.
Total Current Liabilities was $76.9 Mil.
Long-Term Debt & Capital Lease Obligation was $194.0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(30.214 / 150.445) / (24.226 / 140.938)
=0.200831 / 0.171891
=1.1684

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(17.651 / 140.938) / (11.551 / 150.445)
=0.125239 / 0.076779
=1.6312

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (96.505 + 222.565) / 323.482) / (1 - (104.205 + 229.147) / 454.642)
=0.013639 / 0.266781
=0.0511

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=150.445 / 140.938
=1.0675

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(9.234 / (9.234 + 229.147)) / (12.472 / (12.472 + 222.565))
=0.038736 / 0.053064
=0.73

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(31.931 / 150.445) / (27.486 / 140.938)
=0.212244 / 0.195022
=1.0883

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((204.081 + 74.156) / 323.482) / ((194.03 + 76.937) / 454.642)
=0.860131 / 0.596001
=1.4432

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-152.05 - -6.433 - 5.258) / 323.482
=-0.466409

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Avid Bioservices has a M-score of -4.69 suggests that the company is unlikely to be a manipulator.


Avid Bioservices Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Avid Bioservices's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Avid Bioservices Business Description

Traded in Other Exchanges
Address
14191 Myford Road, Tustin, CA, USA, 92780
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.
Executives
Matthew R. Kwietniak officer: Chief Commercial Officer 14191 MYFORD ROAD, TUSTIN CA 92780
Richard A. Richieri officer: Chief Operations Officer 14191 MYFORD ROAD, TUSTIN CA 92780
Nicholas Stewart Green director, officer: President & CEO 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Daniel Ryan Hart officer: Chief Financial Officer 2642 MICHELLE DR., SUITE 200, TUSTIN CA 62780
Mark R Ziebell officer: V.P., General Counsel 14282 FRANKLIN AVENUE, TUSTIN CA 92780
Richard B Hancock director 14282 FRANKLIN AVE., TUSTIN CA 92780
Joseph Carleone director 3883 HOWARD HUGHES PKWY, SUITE 700, LAS VEGAS NV 89169
Gregory Sargen director
Esther M. Alegria director 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Mark R Bamforth director 500 KENDALL ST., CAMBRIDGE MA 02142
Jeanne Thoma director C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Joel Mccomb director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Stephen Michael Hedberg officer: Principal Fin. & Acct. Officer 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780